STOCK TITAN

Dyne Therapeutics Inc - DYN STOCK NEWS

Welcome to our dedicated news page for Dyne Therapeutics (Ticker: DYN), a resource for investors and traders seeking the latest updates and insights on Dyne Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Dyne Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Dyne Therapeutics's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.63%
Tags
earnings
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.28%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.55%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.79%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.57%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.74%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.25%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.32%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.32%
Tags
clinical trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.87%
Tags
management
Dyne Therapeutics Inc

Nasdaq:DYN

DYN Rankings

DYN Stock Data

2.33B
56.41M
0.95%
86.2%
8.32%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Waltham

About DYN

dyne therapeutics, inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the united states. it develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its force platform that delivers disease-modifying therapies. the company was founded in 2017 and is based in waltham, massachusetts.